On Tuesday, VYNE Therapeutics Inc (NASDAQ: VYNE) opened higher 15.96% from the last session, before settling in for the closing price of $0.91. Price fluctuations for VYNE have ranged from $0.85 to $4.30 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 65.87%. Company’s average yearly earnings per share was noted -13.62% at the time writing. With a float of $13.61 million, this company’s outstanding shares have now reached $15.96 million.
Let’s determine the extent of company efficiency that accounts for 13 employees. In terms of profitability, gross margin is 65.95%, operating margin of -7414.88%, and the pretax margin is -6969.42%.
VYNE Therapeutics Inc (VYNE) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of VYNE Therapeutics Inc is 18.32%, while institutional ownership is 36.72%. The most recent insider transaction that took place on Jan 15 ’25, was worth 43,800. In this transaction Director of this company bought 15,000 shares at a rate of $2.92, taking the stock ownership to the 51,472 shares.
VYNE Therapeutics Inc (VYNE) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -13.62% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.71% during the next five years compared to 65.87% growth over the previous five years of trading.
VYNE Therapeutics Inc (NASDAQ: VYNE) Trading Performance Indicators
Check out the current performance indicators for VYNE Therapeutics Inc (VYNE). In the past quarter, the stock posted a quick ratio of 4.47. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 29.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.99, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.73 in one year’s time.
Technical Analysis of VYNE Therapeutics Inc (VYNE)
Looking closely at VYNE Therapeutics Inc (NASDAQ: VYNE), its last 5-days average volume was 0.4 million, which is a jump from its year-to-date volume of 0.2 million. As of the previous 9 days, the stock’s Stochastic %D was 48.65%.
During the past 100 days, VYNE Therapeutics Inc’s (VYNE) raw stochastic average was set at 10.05%, which indicates a significant decrease from 80.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.81% in the past 14 days, which was lower than the 80.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2398, while its 200-day Moving Average is $2.1164. However, in the short run, VYNE Therapeutics Inc’s stock first resistance to watch stands at $1.1400. Second resistance stands at $1.2200. The third major resistance level sits at $1.3300. If the price goes on to break the first support level at $0.9500, it is likely to go to the next support level at $0.8400. Should the price break the second support level, the third support level stands at $0.7600.
VYNE Therapeutics Inc (NASDAQ: VYNE) Key Stats
There are currently 15,210K shares outstanding in the company with a market cap of 17.66 million. Presently, the company’s annual sales total 500 K according to its annual income of -39,830 K. Last quarter, the company’s sales amounted to 200 K and its income totaled -8,610 K.
